Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Mahfoud

Showing results (451-460 of 614) with videos related to

Pageof 62
Sort By:
European Heart Journal. Quality of Care & Clinical Outcomes|September 4, 2022
Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registryRoland E Schmieder, Felix Mahfoud, Giuseppe Mancia, et al.
European Heart Journal|December 8, 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Bhm, Stefan Anker, Felix Mahfoud, et al.
Circulation|April 27, 2011
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot studyFelix Mahfoud, Markus Schlaich, Ingrid Kindermann, et al.
JACC. Cardiovascular Interventions|February 22, 2020
Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of HypertensionFelix Mahfoud, Jean Renkin, Horst Sievert, et al.
European Journal of Heart Failure|September 10, 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Felix Mahfoud, et al.
Journal of Hypertension|May 24, 2013
Renal nerve ablation reduces augmentation index in patients with resistant hypertensionDagmara Hering, Elisabeth A Lambert, Petra Marusic, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 27, 2022
Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trialFelix Mahfoud, Ahmed Farah, Marc-Alexander Ohlow, et al.
Hypertension (Dallas, Tex. : 1979)|June 15, 2023
Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINEFelix Mahfoud, Giuseppe Mancia, Roland E Schmieder, et al.
Hypertension (Dallas, Tex. : 1979)|October 29, 2014
Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failureFaiez Zannad, Wendy Gattis Stough, Felix Mahfoud, et al.
Heart Rhythm|December 6, 2025
Prevalence of arrhythmia-induced cardiomyopathy: A systematic review and meta-analysisTeodor Serban, Tatjana Müller, Sven Knecht, et al.
Pageof 62

Showing results (451-460 of 614) with videos related to

Sort By:
Pageof 62
European Heart Journal. Quality of Care & Clinical Outcomes|September 4, 2022
Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registryRoland E Schmieder, Felix Mahfoud, Giuseppe Mancia, et al.
European Heart Journal|December 8, 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Bhm, Stefan Anker, Felix Mahfoud, et al.
Circulation|April 27, 2011
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot studyFelix Mahfoud, Markus Schlaich, Ingrid Kindermann, et al.
JACC. Cardiovascular Interventions|February 22, 2020
Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of HypertensionFelix Mahfoud, Jean Renkin, Horst Sievert, et al.
European Journal of Heart Failure|September 10, 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Felix Mahfoud, et al.
Journal of Hypertension|May 24, 2013
Renal nerve ablation reduces augmentation index in patients with resistant hypertensionDagmara Hering, Elisabeth A Lambert, Petra Marusic, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 27, 2022
Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trialFelix Mahfoud, Ahmed Farah, Marc-Alexander Ohlow, et al.
Hypertension (Dallas, Tex. : 1979)|June 15, 2023
Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINEFelix Mahfoud, Giuseppe Mancia, Roland E Schmieder, et al.
Hypertension (Dallas, Tex. : 1979)|October 29, 2014
Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failureFaiez Zannad, Wendy Gattis Stough, Felix Mahfoud, et al.
Heart Rhythm|December 6, 2025
Prevalence of arrhythmia-induced cardiomyopathy: A systematic review and meta-analysisTeodor Serban, Tatjana Müller, Sven Knecht, et al.
Pageof 62